Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer

ABSTRACT: Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer

PROVIDER: PRJNA1021168 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer

Project description:The results revealed differences between the RC402-treated and Control samples

2024-09-23 | GSE244046 | GEO

Dnase1l3 enhances antitumor immunity and suppresses tumor progression

Project description:Dnase1l3 enhances antitumor immunity and suppresses tumor progression

| PRJNA803220 | ENA

VEGF blockade enhances the antitumor effect of BRAFV600E inhibition

Project description:VEGF blockade enhances the antitumor effect of BRAFV600E inhibition

| PRJNA286655 | ENA

Dnase1l3 enhances antitumor immunity and suppresses tumor progression [scRNAseq]

Project description:Dnase1l3 enhances antitumor immunity and suppresses tumor progression [scRNAseq]

| PRJNA803189 | ENA

Reovirus low-density particles package viral and cellular RNA

Project description:Packaging of segmented, double-stranded RNA viral genomes requires coordination of multiple viral proteins and RNA segments. For mammalian orthoreovirus (reovirus), evidence suggests either all ten or zero viral RNA segments are simultaneously packaged in a highly coordinated process hypothesized to exclude host RNA. Accordingly, reovirus generates genome-containing virions and “genomeless” top component particles. However, despite ostensibly lacking the genome, top component particles maintain a low level of infectivity. Whether reovirus particles can package host RNA is unknown. To gain insight into reovirus packaging potential and mechanisms, we employed next-generation RNA-sequencing to define the viral and host RNA content of purified reovirus virions and top component particles. Reovirus top component particles contained double-stranded viral RNA segments in similar proportions but at reduced levels compared to virions. Top component particles also were enriched for numerous host RNAs, especially short, non-polyadenylated transcripts, that differed by reovirus strain, independent of the viral polymerase. In contrast, virions were enriched for very few host RNAs. Collectively, these findings indicate that genome packaging into reovirus virions is exquisitely selective, while incorporation of host RNAs into top component particles is more promiscuous or differentially selective and may contribute to or result from inefficient viral RNA packaging.

2021-06-08 | GSE164270 | GEO

Reshaping of the MHC-I ligandome in response to reovirus-based cancer immunotherapy

Project description:Oncolytic viruses (OVs), known for their cancer-killing characteristics, overturn tumor-associated defects in antigen presentation through the MHC class I pathway and induce protective neo antitumor CD8 T cell responses. Nonetheless, whether OVs shape the tumor MHC-I ligandome remains unknown. Here, we investigated if an OV induces the presentation of novel MHC I-bound tumor antigens (termed tumor MHC-I ligands). Using comparative mass spectrometry (MS)-based MHC-I ligandomics, we determined differential tumor MHC-I ligand expression following treatment with oncolytic reovirus in a murine ovarian cancer model. In vitro we found that reovirus induces the presentation of tumor MHC-I ligands in cancer cells. Concurrent multiplexed quantitative proteomics revealed that the changes in tumor MHC-I ligand presentation were mostly independent of reovirus-induced alterations of their source proteins. In an in vivo model, tumor MHC-I ligands were induced by reovirus in tumors but also, more importantly, analysis of spleens (a source of antigen-presenting cells) showed exclusive induction of most MHC-I ligands occurred in tumor-bearing mice. Finally, IFNγ assays demonstrated immunogenicity of the reovirus-induced MHC-I ligands. OV-induced MHC-I responses may be exploited in combinatorial approaches to promote the efficacy of cancer immunotherapies.

2019-05-20 | PXD013066 | Pride

Expresssion data from reovirus treated breast cancer cell lines

Project description:Reovirus mediated cell death of breast cancer is orchestrated via apoptotic cell death pathways We used inhouse microarrays to detail the global programme of gene expression following reovirus treatment

2015-06-13 | GSE69813 | GEO

Dnase1l3 enhances antitumor immunity and suppresses tumor progression [bulk RNAseq]

Project description:Dnase1l3 enhances antitumor immunity and suppresses tumor progression [bulk RNAseq]

| PRJNA803223 | ENA

Callinectes sapidus reovirus 1

Project description:Callinectes sapidus reovirus 1

| PRJNA939818 | ENA

Transcriptome Signature Post Reovirus Treatment In KRAS Mutated Colorectal Cancer

Project description:Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 45-50% of CRC patients possess KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patient samples possessing KRAS mutated metastatic CRC. This is the raw data from the peripheral mononuclear cell (PBMC) samples at 4 timepoints (pre treatment, 48 hours, day 8, and day 15).

2021-05-01 | GSE173636 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data